<DOC>
	<DOCNO>NCT00401622</DOCNO>
	<brief_summary>To assess clinical benefit OneTouch® Ultra®2 BGMS versus standard BGMS 52 week use .</brief_summary>
	<brief_title>Clinical Benefits Blood Glucose Monitoring System Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>· Current diagnosis type 2 diabetes Diagnosed least 3 month prior start study 15 year start study Stable regimen ( i.e. , change therapeutic regimen ) past three month Baseline HbA1c 7.0 8.9 % , inclusive Using insulin Using oral agent target postprandial hyperglycemia ( Note : These medication may add study ) Known history anemia disorder associate anemia Has previously use device test study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>